We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Nicox SA | EU:ALCOX | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.3375 | 0.321 | 0.343 | 0.3495 | 0.321 | 0.327 | 77,036 | 16:40:00 |
Press Release | |||
Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results | |||
| |||
About Nicox | |||
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index.For more information www.nicox.com. | |||
Analyst coverage | |||
Bryan, Garnier & Co Eric Yoo Paris, FranceH.C. Wainwright & Co Yi Chen New York, U.S. | |||
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. | |||
Contacts | |||
NicoxGavin SpencerChief Executive Officer+33 (0)4 97 24 53 00communications@nicox.com | Media / Investors Sophie Baumont Cohesion Bureau +33 6 27 74 74 49 sophie.baumont@cohesionbureau.com | ||
Disclaimer | |||
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 2.7 of the “Rapport Annuel 2022” and in section 4 of the “Rapport semestriel financier et d’activité 2023” which are available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail. | |||
Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 |
Income statement
December 31, 2023 | December 31, 2022 | |
(in thousands of euros) | ||
Sales of services | 257 | 212 |
Royalties for patent grants | 6,646 | 5,241 |
REVENUE | 6,903 | 5,453 |
Reversals of depreciation, amortization, provisions and transfers of expenses | 13 | 97 |
Other income | 225 | - |
TOTAL OPERATING INCOME | 7,141 | 5,550 |
Other purchases and external charges | (18,406) | (18,103) |
Taxes, duties and similar payments | (99) | (184) |
Salaries and wages | (1,764) | (3,053) |
Social security expenses | (739) | (1,177) |
Amortization | (21) | (13) |
Depreciation | - | - |
Provisions for liability and charges | (122) | (41) |
Other expenses | (2,825) | (2,241) |
Exchange loss on receivables and debts | (221) | - |
TOTAL OPERATING EXPENSES | (24,197) | (24,812) |
OPERATING PROFIT (LOSS) | (17,056) | (19,262) |
Other interest and similar income | 1,099 | 1,120 |
Net income from sales of investments securities | - | 1 |
Reversal of provisions, impairment losses and transfer of expenses | 39 | 3 |
Foreign exchange gains | 117 | 872 |
TOTAL FINANCIAL INCOME | 1,255 | 1,996 |
Amortization, depreciation and financial provisions | (3,543) | (12,142) |
Interest and similar expenses | (1,580) | (1,582) |
Foreign exchange loss | (244) | (401) |
Interests on loan | (53) | (49) |
Net expense from sales of investments securities | (200) | (349) |
TOTAL FINANCIAL EXPENSES | (5,621) | (14,523) |
FINANCIAL PROFIT (LOSS) | (4,366) | (12,527) |
PRE-TAX LOSS | (21,422) | (31,789) |
Exceptional income from previous financial year | 63 | - |
EXCEPTIONAL INCOME | 63 | - |
EXCEPTIONAL INCOME (LOSS) | 63 | - |
Research tax credit | 478 | 504 |
NET PROFIT & LOSS | (20,881) | (31,285) |
Balance sheet
December 31, 2023 | December 31, 2022 | |
(in thousands of euros) | ||
ASSETS | ||
Intangible fixed assets | 24 | 1 |
Tangible fixed assets | 26 | 25 |
Financial fixed assets | 1,805 | 4,926 |
FIXED ASSETS | 1,855 | 4,952 |
Trade receivables and related accounts | 3,424 | 2,623 |
Other receivables (1) | 34,324 | 37,844 |
Cash assets | 11,259 | 27,080 |
Prepaid expenses | 886 | 1,481 |
CURRENT ASSETS | 49,893 | 69,028 |
Unrealized foreign exchange losses and valuation differences - Assets | 13 | 36 |
Loan redemption premiums | 1,218 | 1,827 |
TOTAL REGULARISATION ACCOUNTS | 1,231 | 1,863 |
TOTAL ASSETS | 52,980 | 75,843 |
LIABILITIES | ||
Share Capital | 50,170 | 50,100 |
Premiums related to share capital | 529,478 | 529,547 |
Retained earnings | (537,354) | (506,069) |
Net loss for the financial year | (20,881) | (31,285) |
Total shareholders' equity | 21,413 | 42,293 |
Provisions for liabilities | 13 | 39 |
Provisions for charges | 700 | 577 |
Total provisions for liabilities and charges | 713 | 616 |
Loans and debts from lending institutions | 20,895 | 21,259 |
Loans and other financial debts | 4,258 | 4,037 |
Accounts payable and related accounts | 2,499 | 2,537 |
Tax and social security debts | 648 | 1,072 |
Deferred income | 1,918 | 2,169 |
Total current liabilities | 30,218 | 31,074 |
Unrealized exchange gains | 635 | 1,860 |
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 52,980 | 75,843 |
(1) including €32.7 million of receivable with Nicox Ophthalmics Inc’s subsidiary
1 Net revenue consists of revenue from collaborations less royalty payments
Attachment
1 Year Nicox Chart |
1 Month Nicox Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions